Interventional technology developer Cordis Endovascular has introduced a new hydrophilic-coated catheter, Tempo Aqua, in the U.S.
The catheter can be used in selective catheterization, carotid angiography, and chronic total coronary occlusion (CTO) cases, as well as in procedures such as uterine fibroid embolization and subintimal angioplasty, according to the Warren, NJ-based subsidiary of Johnson & Johnson.
By AuntMinnie.com staff writers
June 14, 2005
Related Reading
FDA approves Cypher stent with MRI scans, April 21, 2005
Medtronic loses verdict in Cordis trial, March 15, 2005
Johnson & Johnson to acquire Guidant, December 16, 2004
Court denies Cordis preliminary injunction, May 31, 2004
Cordis releases stent study data, May 26, 2004
Copyright © 2005 AuntMinnie.com
![Representative example of a 16-year-old male patient with underlying X-linked adrenoleukodystrophy. (A, B) Paired anteroposterior (AP) chest radiograph and dual-energy x-ray absorptiometry (DXA) report shows lumbar spine (L1 through L4) areal bone mineral density (BMD). The DXA report was reformatted for anonymization and improved readability. The patient had low BMD (Z score ≤ −2.0). (C) Model (chest radiography [CXR]–BMD) output shows the predicted raw BMD and Z score in comparison with the DXA reference standard, together with interpretability analyses using Shapley additive explanations (SHAP) and gradient-weighted class activation maps. The patient was classified as having low BMD, consistent with the reference standard. AM = age-matched, DEXA = dual-energy x-ray absorptiometry, RM2 = room 2, SNUH = Seoul National University Hospital, YA = young adult.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/ai-children-bone-density.0snnf2EJjr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
